Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.

Naito, S; Sakai, H; Hashine, K; Tomita, Y; Shinohara, N; Fujisawa, M; Eto, M; Ozono, S; Akaza, H

Naito, S; Sakai, H; Hashine, K; Tomita, Y; Shinohara, N; Fujisawa, M; Eto, M; Ozono, S; Akaza, H.

Afiliación

Naito S; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka. Electronic address: naito@uro.med.kyushu-u.ac.jp.
Sakai H; Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki.
Hashine K; Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama.
Tomita Y; Department of Urology, Yamagata University Faculty of Medicine, Yamagata.
Shinohara N; Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo.
Fujisawa M; Department of Urology, Kobe University School of Medicine, Kobe.
Eto M; Department of Urology, Faculty of Life Sciences, Kumamoto University, Kumamoto.
Ozono S; Department of Urology, Hamamatsu University School of Medicine, Hamamatsu.
Akaza H; Department of Strategic Investigation on Comprehensive Cancer Network, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.

Ann Oncol ; 26(9): 1871-1876, 2015 Sep.

Article en En | MEDLINE | ID: mdl-26117830

Asunto(s)

Antineoplásicos/uso terapéutico; Carcinoma de Células Renales/tratamiento farmacológico; Neoplasias Renales/tratamiento farmacológico; Niacinamida/análogos & derivados; Ácido Oxónico/uso terapéutico; Compuestos de Fenilurea/uso terapéutico; Tegafur/uso terapéutico; Adulto; Anciano; Antineoplásicos/efectos adversos; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Supervivencia sin Enfermedad; Combinación de Medicamentos; Femenino; Humanos; Masculino; Dosis Máxima Tolerada; Persona de Mediana Edad; Niacinamida/efectos adversos; Niacinamida/uso terapéutico; Ácido Oxónico/efectos adversos; Compuestos de Fenilurea/efectos adversos; Sorafenib; Tegafur/efectos adversos; Resultado del Tratamiento

Palabras clave

S-1; metastatic renal cell carcinoma; sorafenib

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ácido Oxónico / Compuestos de Fenilurea / Carcinoma de Células Renales / Tegafur / Niacinamida / Neoplasias Renales / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google